What is the lifetime risk of experiencing a first psychotic episode or schizophrenia?
Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, US adult
1 in 143
0.7% lifetime chance
range 1 in 250 to 1 in 83
≈ As likely as
Perceived
Most people carry a vague sense that schizophrenia is rare, severe, and happens to other people — the kind of illness they associate with news stories about violence or homelessness, not with anyone in their social circle. The folk estimate tends to land somewhere around "very unlikely," which is directionally correct for narrow-definition schizophrenia (~0.5- 0.7%) but underestimates the broader category of psychotic experiences, which epidemiological surveys place at 3-5% lifetime. The stigma attached to psychosis suppresses disclosure, reinforcing the perception that it is rarer than it actually is.
Source: editorial intuition, not polled
Actual
~0.5-0.7% lifetime prevalence of schizophrenia in the general population
general adult population
Show derivation
The 2026 systematic review and meta-analysis in Molecular Psychiatry (Jongsma et al.) reports a pooled lifetime prevalence of 0.62% (95% CI: 0.51%-0.76%) across 60 general-population studies in 24 countries. NIMH cites an international prevalence range of 0.33%-0.75% for schizophrenia among non-institutionalised persons, noting that institutionalised and homeless populations are under-counted in household surveys. The 0.7% (1 in 143) point estimate used here sits at the upper end of the NIMH range and within the confidence interval of the meta-analysis, reflecting the likelihood that true prevalence exceeds household-survey estimates because of under-enumeration of affected individuals in institutional settings, shelters, and on the streets. This is a lifetime prevalence figure, not an annual rate compounded — schizophrenia onset is heavily concentrated in adolescence through the early thirties, making annual compounding inappropriate. Uncertainty band: low 0.004 anchors to NIMH's 0.33% floor for non-institutionalised populations; high 0.012 reflects a plausible ceiling once the systematically excluded institutionalised, incarcerated, and homeless populations are accounted for.
Caveats: The 0.7% figure covers schizophrenia specifically, not all psychotic disorders. …
The 0.7% figure covers schizophrenia specifically, not all psychotic disorders. Broader definitions that include schizoaffective disorder, brief psychotic episodes, and substance-induced psychosis push the lifetime rate of any psychotic experience to 3-5%. The normalised figure uses a lifetime prevalence, not an annual rate compounded over 59 years, because schizophrenia onset is concentrated in a narrow age window (late teens to early thirties) and recurrence is not well-modelled by independent annual draws. Household surveys systematically under-count affected individuals who are institutionalised, incarcerated, or homeless, so the true prevalence almost certainly exceeds the survey-derived estimates. Risk is not uniformly distributed: urban birth, migration, cannabis use during adolescence, and family history each elevate individual risk substantially. The 28.5-year average life-years-lost figure cited by NIMH reflects both the severity of the condition and the downstream effects on physical health, social integration, and access to care.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Mental health LTD claim
What are the odds of filing a long-term disability claim for a mental health condition?
Cat litter toxoplasmosis
What are the odds of acquiring a toxoplasma infection from cleaning a cat's litter box?
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The “1% lifetime risk” figure for schizophrenia has circulated in textbooks for decades, but contemporary evidence narrows it. A 2026 systematic review and meta-analysis in Molecular Psychiatry — pooling 60 general-population studies across 24 countries with a combined sample exceeding 20 million — reports a pooled lifetime prevalence of 0.62% (95% CI: 0.51%-0.76%). NIMH places the US-specific range at 0.33%-0.75% among non-institutionalised persons, with an explicit caveat that affected individuals in prisons, long-term care, and homeless populations are systematically under-counted. The working estimate of roughly 1 in 143 (0.7%) used here sits at the upper end of both ranges, reflecting the under-enumeration problem rather than a preference for dramatic numbers.
The broader category of psychotic experiences — including brief psychotic episodes, schizoaffective disorder, and substance-induced psychosis — carries a lifetime prevalence of roughly 3-5%, making “any psychotic experience” about as common as bipolar disorder. The gap between “schizophrenia” and “any psychosis” matters because public perception collapses the two: most people who hear “psychotic episode” picture the chronic, disabling trajectory of schizophrenia, not the transient, resolving episodes that account for the majority of first presentations. Nearly 80% of patients experiencing a first episode of schizophrenia will eventually recover, though up to 70% will have a second psychotic episode within five to seven years — a relapse rate that is high but that also means a substantial fraction achieves long-term remission.
The risk is not uniformly distributed. Onset is concentrated between the late teens and early thirties, with males tending to present earlier (late adolescence to early twenties) than females (early twenties to early thirties). Urban birth, migrant status, adolescent cannabis use, and family history each elevate individual risk by factors that are clinically meaningful. NIMH notes that schizophrenia is one of the top 15 leading causes of disability worldwide, and that the estimated average potential life lost is 28.5 years in the US — a figure that reflects not only the disease itself but the cascading effects on physical health, employment, housing, and social connection. The condition is roughly as common as the population estimates suggest — neither dramatically rarer nor dramatically more common than the clinical consensus holds — but its consequences are severe enough that even a sub-1% lifetime probability translates into a large absolute burden.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] National Institute of Mental Health (NIMH) — Schizophrenia — Statistics
Schizophrenia — Statistics- Statistic
The international prevalence of schizophrenia among non-institutionalized persons is 0.33% to 0.75%- Excerpt
“"Precise prevalence estimates of schizophrenia are difficult to obtain due to clinical and methodological factors such as the complexity of schizophrenia diagnosis, its overlap with other disorders, and varying methods for determining diagnoses. The international prevalence of schizophrenia among non-institutionalized persons is 0.33% to 0.75%. Individuals with schizophrenia and other psychotic disorders may be under-counted in prevalence estimation studies." ”
- Source data from
- 2024-04-01
- Accessed
- 2026-04-24 · archived copy
- Calculation
- NIMH provides the 0.33%-0.75% range for non-institutionalised persons, explicitly noting under-counting of institutionalised and homeless individuals. This establishes the floor for the true US prevalence. The estimated average potential life lost of 28.5 years for individuals with schizophrenia in the US contextualises the severity. Used here as the authoritative US-government source anchoring the lower bound.
-
[2] Molecular Psychiatry / Nature — Global lifetime prevalence of schizophrenia: A systematic review and meta-analysis
Global lifetime prevalence of schizophrenia: A systematic review and meta-analysis- Statistic
Pooled lifetime prevalence of schizophrenia in the general population: 0.62% (95% CI: 0.51%-0.76%)- Excerpt
“"The lifetime prevalence of schizophrenia is 0.62% (95% CI [0.51%–0.76%]) in the general population. Asia has the lowest lifetime prevalence of schizophrenia in the general population, at 0.47% (95% CI [0.35%–0.64%]). Schizophrenia is more prevalent in special populations than in the general population." ”
- Source data from
- 2026-03-01
- Accessed
- 2026-04-24 · archived copy
- Calculation
- This 2026 meta-analysis is the most comprehensive pooled estimate available, drawing on 60 general-population studies across 24 countries with a combined sample of over 20 million individuals. The 0.62% central estimate and 0.51%-0.76% confidence interval provide the statistical backbone for the normalized figure. The point estimate of 0.7% used for lifetime_us_adult sits at the upper edge of this CI, justified by NIMH's observation that US household surveys under-count institutionalised and homeless individuals with schizophrenia.
- Independence
- Methodologically independent of NIMH's range: the meta-analysis pools primary epidemiological studies worldwide using a systematic search protocol, whereas NIMH's figure synthesises US-focused surveillance and review literature.